Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. Anastassopoulou
Pin53 - Is the Recombinant Zoster Vaccine Also Cost-Effective for the German Population ≥50 Years of Age?
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Cost-Effectiveness of the Recommendations of the Advisory Committee on Immunization Practices for the Recombinant Adjuvanted Zoster Subunit Vaccine
JAMA Internal Medicine
Internal Medicine
Cost-Effectiveness of an Adjuvanted Recombinant Zoster Vaccine in Older Adults in the United States Who Have Been Previously Vaccinated With Zoster Vaccine Live
Human Vaccines and Immunotherapeutics
Medicine
Allergy
Immunology
Pharmacology
Universal Varicella Vaccination Reduced the Incidence of Herpes Zoster in Vaccine Recipients 1 to 4 Years of Age
Journal of Dermatological Science
Dermatology
Biochemistry
Molecular Biology
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation
JAMA - Journal of the American Medical Association
Medicine
Clarification Regarding the Statement of the Association Between the Recombinant Zoster Vaccine (RZV) and Gout Flares
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Recombinant Human DNase (rhDNase) in Cystic Fibrosis: Is It Cost Effective?
Archives of Disease in Childhood
Child Health
Pediatrics
Perinatology
Child Maltreatment Is Associated With Poor Socioeconomic Outcomes at 50 Years of Age
Archives of Disease in Childhood: Education and Practice Edition
Child Health
Pediatrics
Perinatology
Pin56 - Cost-Effectiveness of Varicella and Herpes Zoster Vaccination in the Swedish Population
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Zoster Vaccine Live
Pharmacotherapy
Pharmacology
